Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | PHASE1 | COMPLETED | 46 | — | — | Jul 1, 2009 | Nov 1, 2012 | May 22, 2013 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| MDX-1203 | EXPERIMENTAL | Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study |
| Name | Type | Description |
|---|---|---|
| MDX-1203 | BIOLOGICAL | Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 * Criteria specific to each tumor type: * For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease. Must have failed at least 1 prior systemic therapy * For B-cell non-Hodgkin's lymph...